IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells

Cell Cycle

Volumn 9, Issue 17, 2010, Pages 3423-3427

  Liu, Yan ^a   Fuchs, James ^a   Li, Chenglong ^a   Lin, Jiayuh ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Interleukin 6; JAK1; JAK2; STAT1; STAT3

Indexed keywords

CURCUMIN; FLLL 32; INHIBITOR PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; HEPATITIS B; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PANCREAS CANCER; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77956409919     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.17.12946     Document Type: Review

References (21)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-76.
2. Tabor E. Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001; 33:115-7.
3. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009; 1155:206-21.
4. Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors and screening. Semin Liver Dis 2005; 25:143-54. (Pubitemid 40781067)
5. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-4. (Pubitemid 47056470)
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127:35-50.
7. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8:2.
8. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: Validation of utility as a clinical marker. Ann Surg 1998; 227:398-404. (Pubitemid 28131021)
9. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann NY Acad Sci 2002; 963:46-52. (Pubitemid 34721694)
10. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin- 6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008; 19:353-8. (Pubitemid 351201719)
11. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124:2766-70.
12. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140:197-208.
13. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502-12.
14. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 2000; 31:149-59. (Pubitemid 30033701)
15. Galun E, Zeira E, Pappo O, Peters M, Rose-John S. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 2000; 14:1979-87.
16. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Inoue H, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003; 112:989-98. (Pubitemid 38056314)
17. Liu Y, Li PK, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010.
18. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70:2445-54.
19. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251:199-210.
20. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171:3863-71. (Pubitemid 37254592)
21. Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem Pharmacol 2006; 72:1547-54. (Pubitemid 44666746)